Melanoma | Virtual Congress

Disease Education

Disease Education Clinical Trials

.atomic-select.jsAtomicSelect { display: none; }

Disease Education

Disease Education Clinical Trials

Learn About the Impact of BRAF Mutation Status in Advanced Melanoma

Prognostic Indicators of Recurrence and Survival in Advanced Melanoma

Learn more about the prevalence of melanoma, as well as the prognostic indicators of survival and relapse rate associated with advanced stage melanomas.

Exploring the Potential of MAPK Inhibition in Melanoma

Learn more about hyperactivated MAPK pathway signaling and targeted inhibition of the protein kinases in BRAF+ melanoma.

Explore Clinical Trials

NCT04417621

LXH254 Combinations in 𝘉𝘙𝘈𝘍 V600 or 𝘕𝘙𝘈𝘚-Mutant Melanoma

Explore Compounds

Spartalizumab (PDR001)

PD-1–targeting monoclonal antibody

Compound(s) are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established and there is no guarantee that they will become commercially available for the use(s) under investigation.

MOA data are based on in vitro/in vivo data.

.lazy { display: none; }

Use of website is governed by the Terms of Use and Privacy Policy.

10/22 121333-3